LungLife AI, Inc. (AIM:LLAI)
London · Delayed Price · Currency is GBP · Price in GBX 4.150
-0.100 (-2.35%)
Inactive · Last trade price on May 28, 2025
LungLife AI Company Description
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China.
The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan.
The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019.
LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
LungLife AI, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Paul Pagano |
Contact Details
Address: 2545 West Hillcrest Drive Thousand Oaks, Delaware 91320 United States | |
| Phone | 805 409 9868 |
| Website | lunglifeai.com |
Stock Details
| Ticker Symbol | LLAI |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | USU5500L1045 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Paul Pagano | Chief Executive Officer |
| David Anderson | Chief Financial Officer |